<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824976</url>
  </required_header>
  <id_info>
    <org_study_id>BB-01</org_study_id>
    <nct_id>NCT04824976</nct_id>
  </id_info>
  <brief_title>Effects of Blueberries on Symptoms and Underlying Mechanisms of Functional Gastrointestinal Disorders</brief_title>
  <official_title>Effects of Blueberries on Symptoms and Underlying Mechanisms of Functional Gastrointestinal Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brain-Gut Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brain-Gut Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is extensive pre-clinical evidence for potential health effects of blueberries. These&#xD;
      are related, but not exclusively due to their high polyphenol content. This translational,&#xD;
      clinical, randomized, cross-over, double-blind, placebo-controlled study will investigate the&#xD;
      effects of blueberries in freeze-dried powder form on gastrointestinal and&#xD;
      extra-gastrointestinal symptoms and function, as well as specific potential underlying&#xD;
      mechanisms, in patients with the overlapping functional gastrointestinal disorders, irritable&#xD;
      bowel syndrome and functional dyspepsia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>before and after 6 weeks of each treatment arm</time_frame>
    <description>Validated scale of GI symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive neurological function tests</measure>
    <time_frame>before and after 6 weeks of each treatment arm</time_frame>
    <description>Cambridge Cognition neurocognitive test battery (CANTAB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in musculoskeletal symptoms</measure>
    <time_frame>before and after 6 weeks of each treatment arm</time_frame>
    <description>Validated Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in breath gas concentrations and symptoms scores during fructose breath testing</measure>
    <time_frame>before and after 6 weeks of each treatment</time_frame>
    <description>AUCs (areas under curve) of hydrogen, methane and symptom scores during fructose breath tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory markers for advanced glycation end products, tight junction proteins</measure>
    <time_frame>before and after 6 weeks of each treatment</time_frame>
    <description>Validated biochemical markers of advanced glycation, tight junction protein quantification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Functional Gastrointestinal Disorders</condition>
  <arm_group>
    <arm_group_label>Blueberry</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Freeze-dried pure blueberry powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin powder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberry</intervention_name>
    <description>freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal</description>
    <arm_group_label>Blueberry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched powder maltodextrin twice daily = 60kcal</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fifty-five successive male or female patients with Functional Gastrointestinal&#xD;
             Disorders FGID) enrolled from our Gastroenterology Group Practice (GGP) in Bern,&#xD;
             Switzerland, classified as having either Irritable Bowel Syndrome (IBS), Functional&#xD;
             Dyspepsia (FD) or both according to Rome 4 criteria (Drossman et al 2016; Schmulson et&#xD;
             al. 2017)&#xD;
&#xD;
          -  Age between 18 and 50 years&#xD;
&#xD;
          -  Body mass index 18.5-29.9 kg/m2&#xD;
&#xD;
          -  European / Caucasian ethnicity&#xD;
&#xD;
          -  Able to give informed consent in German as documented by signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of clinically significant disease, as assessed by usual clinical practice&#xD;
             (history, blood and stool tests, imaging and endoscopy, as clinically required) and by&#xD;
             investigator.&#xD;
&#xD;
          -  Colonoscopy, antibiotics or probiotics within 2 weeks before or during the study.&#xD;
&#xD;
          -  Planned dietary modifications (including polyphenol-rich fruit or vegetable smoothies,&#xD;
             drinks or diets) or initiation of new treatments during the study period, besides the&#xD;
             study interventions.&#xD;
&#xD;
          -  Inability or contraindications to undergo the investigated intervention&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clive Wilder-Smith, MD</last_name>
    <phone>+41313123737</phone>
    <email>info@braingut.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology Group Practice / Brain-Gut Research Group</name>
      <address>
        <city>Bern</city>
        <zip>3011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clive Wilder-Smith, MD</last_name>
      <phone>+41313123737</phone>
      <email>info@ggp.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brain-Gut Research Group</investigator_affiliation>
    <investigator_full_name>Clive H Wilder-Smith, MD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

